AGP Executive Report
Last update: 11 hours agoBiotech Momentum: Noxopharm shares jumped 43% after new preclinical data boosted its Sofra platform’s cancer-fighting case, keeping investor attention on next-gen immuno-oncology beyond today’s checkpoint playbook. Deal Watch: Recce Pharmaceuticals is pushing deeper into the Middle East and North Africa, signing a term sheet for a 10-year exclusive licensing path for its R327G topical gel for diabetic foot infections. Clinical Trials Reality Check: A panel on International Clinical Trials Day argues “meaningful progress” now means faster decisions with clearer direction—speed plus better early signals, not just more testing. Tech for Health: A new brain-implant study shows people with paralysis typing near smartphone speed using thought-controlled AI translation. AI Culture & Work: The Hankyoreh Human and Digital Forum tackles how generative AI is reshaping jobs and learning, using a real-world automation lesson to warn against simplistic “technology kills work” stories. Fact Check: A viral claim that cucumbers can “cure” diabetes is flatly unsupported in humans—at best, they’re part of a healthy diet.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
